摘要
大剂量甲氨蝶呤是治疗骨肉瘤及血液系统肿瘤的基石,但其药效学及不良反应存在个体差异。亚甲基四氢叶酸还原酶C667T基因多态性可能与血药浓度及不良反应相关,但并未得到一致结论。本文通过查阅国内外文献,对目前在骨肉瘤血液系统肿瘤中甲氨蝶呤与亚甲基四氢叶酸还原酶C667T基因多态性血药浓度及不良反应相关性进行系统阐述,以期为临床实践提供依据。
High-dose methotrexate is still the cornerstone of the treatment for osteosarcoma and hematologic tumors,but there are individual differences in pharmacodynamics and adverse reactions.Methyltetrahydrofolate reductase C667T gene polymorphism may be associated with blood drug concentration and adverse reactions,but no consistent conclusions have been drawn.Therefore,by referring to domestic and foreign literatures,this paper systematically elaborates the correlation between the blood drug concentration and adverse reactions of methotrexate and methyltetrahydrofolate reductase C667T gene polymorphism in osteosarcoma and hematologic tumors,in order to provide evidence for clinical practice.
作者
武丹威
杜欣
朱思源
董迪
甄健存
张威
Wu Danwei;Du Xin;Zhu Siyuan;Dong Di;Zhen Jiancun;Zhang Wei(Department of Pharmacy,Beijing Jishuitan Hospital,Beijing 100035,China)
出处
《实用药物与临床》
CAS
2022年第12期1142-1147,共6页
Practical Pharmacy and Clinical Remedies
关键词
亚甲基四氢叶酸还原酶
甲氨蝶呤
不良反应
Methylenetetrahydrofolate reductase
Methotrexate
Adverse reactions
